KFDA approves Erivedge for basal cell carcinoma

The Korea Food and Drug Administration said Tuesday that it approved Erivedge (vismodegib 150 mg) as a new treatment for adult patients with basal cell carcinoma, the most common type of skin cancer.

Developed by South San Francisco based-Genentech, a member of the Roche Group, Erivedge is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery...